Insmed Incorporated
INSM
Rangering i aksjer
#1108
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Aksjekurs
$95.88
Markedsverdi
$20.94B
Endring (1 dag)
0.61%
Endring (1 år)
-42.90%
Land
US
Handel Insmed Incorporated (INSM)
Kategori
Healthcare
P/B-forhold for Insmed Incorporated (INSM)
P/B-forhold per October 2026 TTM: 28.06
Ifølge Insmed Incorporated sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 28.06. Ved slutten av 2023 hadde selskapet et P/B-forhold på -13.11.
P/B-historikk for Insmed Incorporated fra 2000 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 28.06 | -29.30% |
| 2024 | 39.69 | -402.68% |
| 2023 | -13.11 | -146.91% |
| 2022 | 27.95 | 275.67% |
| 2021 | 7.44 | -36.83% |
| 2020 | 11.78 | 52.62% |
| 2019 | 7.72 | 59.41% |
| 2018 | 4.84 | -15.80% |
| 2017 | 5.75 | 8.54% |
| 2016 | 5.30 | 55.48% |
| 2015 | 3.41 | -4.67% |
| 2014 | 3.57 | -13.87% |
| 2013 | 4.15 | 182.67% |
| 2012 | 1.47 | 176.73% |
| 2011 | 0.53 | 22.38% |
| 2010 | 0.43 | -45.13% |
| 2009 | 0.79 | -103.91% |
| 2008 | -20.23 | -345.58% |
| 2007 | 8.24 | 36.28% |
| 2006 | 6.04 | -33.73% |
| 2005 | 9.12 | -23.38% |
| 2004 | 11.90 | 195.16% |
| 2003 | 4.03 | 549.88% |
| 2002 | 0.62 | -70.50% |
| 2001 | 2.10 | 220.36% |
| 2000 | 0.66 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 6.251 | -77.72% |
US
|
|
| 13.2547 | -52.76% |
US
|
|
| 4.208 | -85.00% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -77.97% |
NL
|
